- Home
- RNAC vs TNXP Comparison
RNAC vs TNXP Comparison
Compare RNAC & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNAC | TNXP |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.1M | 220.5M |
| IPO Year | 2016 | 2008 |
Fundamental Metrics
Financial Performance| Metric | RNAC | TNXP |
|---|---|---|
| Price | $8.12 | $13.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | $35.00 | ★ $70.00 |
| AVG Volume (30 Days) | 176.5K | ★ 279.9K |
| Earning Date | 06-15-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,797,000.00 | ★ $10,094,000.00 |
| Revenue This Year | N/A | $7.00 |
| Revenue Next Year | $26.02 | $708.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 29.94 |
| 52 Week Low | $5.98 | $12.80 |
| 52 Week High | $17.42 | $69.65 |
Technical Indicators
Market Signals| Indicator | RNAC | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 38.58 |
| Support Level | $6.41 | N/A |
| Resistance Level | $10.49 | $20.36 |
| Average True Range (ATR) | 0.82 | 0.70 |
| MACD | 0.13 | 0.02 |
| Stochastic Oscillator | 61.17 | 34.12 |
Price Performance
Historical ComparisonAbout RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.